| ID | Components | Size (96 tests) | Size (480 tests) |
|---|---|---|---|
| A006-214 | Human LDL R | 35 μg | 160 μg |
| A007-214 | Biotinylated Human PCSK9 | 10 μg | 10 μg |
| A003-214 | Streptavidin-HRP | 10 μg | 10 μg |
| PC9-NA003 | Anti-PCSK9 Neutralizing Antibody | 40 μg | 200 μg |
This pair is useful for screening for inhibitors of human PCSK9 binding to human LDL R.
Upon receipt, please store all items at -70℃.
After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 1 year in lyophilized state;
-70℃ for 1 year under sterile conditions after reconstitution
This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new PCSK9 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human LDL R and in-house developed biotinylated PCSK9 protein. This product is uniquely suitable for rapid high-throughput screening of putative PCSK9 inhibitors. Briefly, we provide you with a biotinylated human PCSK9 protein, a human LDL R protein, an anti-PCSK9 neutralizing antibody (as method verified Reference), and Streptavidin-HRP reagent. Your experiment will include 4 simple steps:
a) Coat the plate with human LDL R.
b) Add your molecule of interest to the plates.
c) Add human PCSK9-Biotin to the plates.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit PCSK9: LDL R binding will be determined by comparing OD readings among different experimental groups.
Binding of Biotinylated Human PCSK9 to Immobilized Human LDL R in a Functional ELISA Assay.
Immobilized human LDL R protein at 3 μg/mL (100 μL/well) can bind biotinylated human PCSK9 with a linear range of 0.000625-0.02 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting.
Inhibition of PCSK9 [Biotinylated] : LDL R Binding by Anti-PCSK9 Neutralizing Antibody.
Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL) were added into PCSK9: biotinylated LDL R binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.
Price(USD) : $600.00
Price(USD) : $2150.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z